KALV (KalVista Pharma) Net Profit

KALV (KalVista Pharmaceuticals, Inc.) - company brandmark

KalVista Pharmaceuticals (KALV) delegates the development of dosage forms and clinical trials to external contractors, focusing on transitioning from injections to tablet forms for the therapy of hereditary angioedema. This chart of the company's price action reflects the -0.21 indicator. The issuer's position is protected by exclusive patents and orphan drug status, which, combined with massive R&D expenditures, blocks new entrants from the market.

KALV (KalVista Pharmaceuticals) Net Profit history from 07/04/2022 to 06/21/2026

Analytical breakdowns and data insights for company KalVista Pharmaceuticals, Inc. (KALV)

- price and consensus price forecast:
Stock Quotes KalVista Corp|KALV - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization KalVista Corp|KALV - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share KalVista Pharmaceuticals|KALV - Book Capitalization|Market Capitalization to Book Value kalvista.com|KALV - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio KalVista Pharmaceuticals|KALV - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio KalVista Pharma|KALV - Company Total Debt|Debts to Book Capitalization KalVista Corp|KALV - Company Long-Term Debt|Company Short-Term Indebtedness KalVista Pharmaceuticals|Immediate Liquidity kalvista.com
- net income and valuation multiples indicators:
KALV - Company Net Income
Summary company analysis:KalVista Pharmaceuticals
Core merchandise of KalVista Pharmaceuticals Inc

For the biopharmaceutical pioneer in hereditary angioedema therapy, KalVista Pharmaceuticals (KALV), this indicator reflects the commercialization efficiency of its unique oral medications. The metric is calculated as the difference between total revenues and all operating expenses, including R&D costs. By analyzing the company's net profitability, an investor identifies the transition stage from development to profit extraction. A downward curve signals a critical increase in costs, while steady growth confirms the market value of KalVista Pharmaceuticals (KALV) innovations.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN - Company Net Income|PHAR - Net Profit|NKTR: Net Profit|upstreambio.com (UPB) - Net Profit|Company Net Income Zenas Biopharma|Company Net Income IMNM|Net Income GOSS (Gossamer Corp)|Company Net Income SEPN (Septerna Pharma)|Net Profit PVLA (Pieris Pharmaceuticals)|Net Financial Result savarapharma.com (SVRA)|RIGL - Company Net Income|Net Financial Result AnaptysBio Inc ANAB|ATXS (Astria Pharma) - Net Income|ENGN: Profit After Payment of Taxes|RAPT (RAPT Therapeutics, Inc.) - Net Profit|Net Profit Aerovate|Net Income ACRS (Aclaris Therapeutics, Inc.)|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Company Net Income Tiziana Life Sciences PLC TLSA|CABA (Cabaletta Bio Inc) - Profit After Tax|Ventyx Biosciences - Net Profit|Final Profit THTX (theratech.com)|AVTX: Net Profit|Eledon Pharmaceuticals Inc. (ELDN) - Net Profit|Company Net Income Agenus Inc|CLYM: Final Profit|Company Net Income Zura Bio Limited (ZURA)|Net Income atyrpharma.com ATYR|Net Profit ADAG (Adagene Inc.)|Net Profit ImageneBio IMA|Shattuck Therapeutics - Net Profit|Equillium, Inc. (EQ) - Net Income|CNTB: Net Profit|Company Net Income Immunic (IMUX)|Net Income ATRA|Net Profit InflaRx GmbH|Net Income XFOR (X4 Pharma)|Profit After Payment of Taxes ACET|Net Profit CELU (Celularity)|Net Financial Result inmunebio.com (INMB)|Barinthus Biotherapeutics plc - Net Profit|Kezar Life Sciences Inc. (KZR) - Net Income|SABS: Net Profit|Akari Therapeutics, Plc (AKTX) - Net Profit|Company Net Income Enlivex Therapeutics Ltd|Company Net Income QTTB|Company Net Income GeoVax (GOVX)|Net Financial Result Edesa Biotech Inc|Company Net Income iBio Corp IBIO|Net Profit Carisma Therapeutics Inc CARM|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|APVO (Aptevo Therapeutics Inc.) - Company Net Income|Net Income AIM|Company Net Income ADTX|Company Net Income GRI Bio, Inc. (GRI)|XRTX: Profit After Tax|Net Profit HIND (Vyome Holdings)|Final Profit REVB|Indaptus - Net Profit|SCNI - Net Profit|calcimedica.com (CALI) - Company Net Income|Affimed N.V. - Final Profit|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Profit IGMS|Net Profit iTeos Pharma (ITOS)|Ocean Biomedical, Inc. - Net Income|Final Profit TCBP|Third Harmonic Bio, Inc. - Net Profit